Krystal Biotech (KRYS) Upgraded to Buy by Zacks Investment Research
Zacks Investment Research upgraded shares of Krystal Biotech (NASDAQ:KRYS) from a hold rating to a buy rating in a research note released on Saturday. They currently have $18.00 price target on the stock.
According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “
Several other brokerages have also recently weighed in on KRYS. LADENBURG THALM/SH SH set a $38.00 price target on shares of Krystal Biotech and gave the stock a buy rating in a research report on Thursday, July 19th. Chardan Capital reiterated a buy rating and set a $35.00 price objective on shares of Krystal Biotech in a research report on Monday, August 6th. William Blair assumed coverage on shares of Krystal Biotech in a research report on Monday, August 6th. They set a buy rating on the stock. Finally, ValuEngine upgraded shares of Krystal Biotech from a sell rating to a hold rating in a research report on Wednesday, May 2nd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $30.33.
Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 6th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.12. sell-side analysts expect that Krystal Biotech will post -1.04 EPS for the current year.
In related news, CFO Antony A. Riley bought 2,800 shares of the stock in a transaction dated Tuesday, May 22nd. The stock was purchased at an average cost of $10.75 per share, with a total value of $30,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Suma Krishnan bought 25,000 shares of the stock in a transaction dated Wednesday, June 6th. The shares were bought at an average cost of $11.02 per share, with a total value of $275,500.00. The disclosure for this purchase can be found here. Insiders own 45.80% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC purchased a new stake in shares of Krystal Biotech during the fourth quarter valued at $266,000. BlackRock Inc. boosted its stake in shares of Krystal Biotech by 75.4% during the second quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock valued at $194,000 after purchasing an additional 5,607 shares during the period. Finally, Acadian Asset Management LLC boosted its stake in shares of Krystal Biotech by 552.2% during the second quarter. Acadian Asset Management LLC now owns 12,202 shares of the company’s stock valued at $182,000 after purchasing an additional 10,331 shares during the period. 29.92% of the stock is owned by hedge funds and other institutional investors.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Further Reading: What is a Leveraged Buyout (LBO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.